18F-DCFBC PET/CT with Multiparametric MRI and Histopathology - Liza Lindenberg
Prostate-specific membrane antigen (PSMA) is over-expressed in prostate cancer, so it is a good target to use for diagnoses and treatment. 18F-DCFBC binds to the external domain of PSMA, so when it is used as a PET tracer it can be very helpful in improving imaging of localized and metastatic prostate cancer. The goal of this research is to asses the ability of 18F-DCFBC to differentiate between benign and malignant lesions in localized prostate cancer and correlate that with multiparametric MRI (mpMRI) and then use the gold-standard of histopathology.
Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer
PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Liza Lindenberg MD is a medical school graduate from the Uniformed Services University of the Health Sciences and was an Army physician for over 14 years prior to transferring to the US Public Health Service and MIP in 2010. She is board certified in Nuclear Medicine and Family Medicine. Her research interests include PET tracers as biomarkers for therapeutic response in cancer treatments.
Ismail Baris Turkbey obtained his medical degree from Hacettepe University in Ankara, Turkey in 2003. He completed his residency in Diagnostic and Interventional Radiology at Hacettepe University. He joined Molecular Imaging Program, National Cancer Institute, NIH in 2007. His main research areas are imaging of prostate cancer (multiparametric MRI, PET CT), prostate biopsy techniques, focal therapy for prostate cancer and image processing (segmentation, decision support systems).